MEASuRE: Metreleptin Effectiveness And Safety Registry
Chiesi Farmaceutici S.p.A. · Generalised Lipodystrophy · Partial Lipodystrophy
Not applicable
Recruiting
100
2026-07
Industry sponsor intelligence
Chiesi Farmaceutici S.p.A.Clinical Pipeline.
Lead-sponsor view of Chiesi Farmaceutici S.p.A.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 2
- Active
- 1
- Completed
- 0
- Results posted
- 0
- Avg enrollment
- 47
Pipeline overview
Programs by phase and activity.
Velocity
Chiesi Farmaceutici S.p.A. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
2phase labels
Early Phase 10
Phase 10
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Metreleptin → | 3 | 0 | 0 | 2 | 0 | 3 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Chiesi Farmaceutici S.p.A. · Familial Partial Lipodystrophy
Phase 3
Recruiting
24
2026-07
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Chiesi Farmaceutici S.p.A. · Partial Lipodystrophy
Phase 3
Active, not recruiting
69
2026-06
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All Chiesi Farmaceutici S.p.A. studies.
This page groups studies where Chiesi Farmaceutici S.p.A. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT02325674MEASuRE: Metreleptin Effectiveness And Safety RegistryJul 16, 2026NCT06679270Open-label Extension Study to Evaluate Metreleptin in Patients With Partial LipodystrophyJul 16, 2026NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PLJun 15, 2026